Roche has licensed Simcere Zaiming’s preclinical trispecific antibody SIM0660, paying $75 million (€65 million) upfront in a ...
B-cell lymphoma is a type of non-Hodgkin lymphoma. It’s also the most common type of lymphoma. Approximately 85% of all lymphomas in the United States are B-cell lymphomas. Non-Hodgkin lymphomas are ...
Greater understanding of the potential role played by B cells in autoimmune disease has spurred an interest in targeting B cells therapeutically. Greater understanding of the potential role played by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results